Patovax is a biotechnology start-up out of Johns Hopkins organized around commercializing RGVax, the first low-cost Human Papillomavirus (HPV) vaccine targeting all clinically relevant type. Based in Maryland but with faciilites now also in Buffalo NY, the firm is focused on development of an universal HPV vaccine. With the objective of providing prophylaxis against all HPV-related cancers and diseases, the firm's pilot vaccine offer the promise of potentially providing protection against all 15 oncogenic HPVs and others that cause various warts.
